Why the study?
Does low-dose acetylsalicylic acid prolong bleeding time and inhibit platelet aggregation in patients with cerebrovascular disease?
Does low-dose acetylsalicylic acid prolong bleeding time and inhibit platelet aggregation in patients with cerebrovascular disease?
Low-dose acetylsalicylic acid (50-70 mg/day) produces a significant in vivo prolongation of bleeding time and inhibition of platelet aggregation in patients with cerebrovascular disease.
Answers are grounded in this paper and cite their sources.
Supports low-dose acetylsalicylic acid for antiplatelet effect in cerebrovascular disease; confirms mechanism in this RCT population.
Platelet aggregation and bleeding time was measured in 43 cerebrovascular patients participating in a controlled double-blind study of low-dose acetylsalicylic acid. In 19 patients with satisfactory inhibition of the platelet aggregation obtained by 50 to 70 mg acetylsalicylic acid per day the bleeding time averaged 11.2 minutes in contrast to 7.0 minutes in the placebo group, p less than 0.001. This study confirms our previous findings of platelet inhibition by low-dose acetylsalicylic acid in patients with cerebrovascular disease. The prolongation of the bleeding time demonstrates that we are dealing not merely with an in vitro phenomenon but with a significant in vivo effect. The study provides the rationale for clinical evaluations of low-dose acetylsalicylic acid in stroke prophylaxis.
No takes yet. Share an insight, caveat, or question.
Boysen et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: